Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Aspirin may alter fallopian tubes, early study hints at cancer prevention

NCT ID NCT03771651

Knowledge-focused Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether taking a low dose of aspirin daily for two weeks before surgery can change the immune environment of the fallopian tubes. Researchers will compare tissue from 18 women who take aspirin to control samples, looking for signs of reduced inflammation and lower cancer-related changes. The goal is to understand if aspirin could one day help prevent fallopian tube cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aspirin 81 mg
What this could lead to
If successful, this could point toward a simple, low-cost way to reduce fallopian tube inflammation and potentially lower cancer risk.
What could go wrong
This is a very early, small pilot study with only 18 participants. It looks at biological changes, not actual cancer prevention, so results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

18 people

The number who actually took part.

Started

Mar 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women undergoing gynecologic surgery for presumed benign indications that includes the removal of their fallopian tubes. This may include sterilization procedures, hysterectomy or partial or full adnexectomy. * Eligible women will have fulfilled their childbearing desires * Age \> 21 Considered low risk for prevalent fallopian tube cancer (not undergoing risk reducing surgery for a known BRCA mutation or other known hereditary predisposition syndrome, family history of ovarian cancer in a first degree relative. Exclusion Criteria: * Males * Women who have presumed or known gynecologic cancer * Women less than 21 years of age * Women currently on either regular aspirin therapy, non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen or chronic steroidal anti-inflammatory medications. * Women with known bleeding diathesis or bleeding disorder. * Women who do not consent for removal of both fallopian tubes. * Women with a history of gastritis or peptic ulcer disease requiring treatment. (Patients with a history of occasional H1 or H2 blocker use for gastro esophageal reflux disease are NOT excluded). * Women with reported aspirin or NSAID allergy * Women with asthma and/or nasal polyps

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm salpingitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube cancer Fallopian tube infection

Contacts and locations

Locations

  • Stephenson Cancer Center, University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.